​

Sangamo Therapeutics (SGMO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SGMO Stock Forecast

Sangamo Therapeutics (SGMO) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $7.25, with a high of $19.00 and a low of $2.00. This represents a 1128.81% increase from the last price of $0.59.

- $4 $8 $12 $16 $20 High: $19 Avg: $7.25 Low: $2 Last Closed Price: $0.59

SGMO Stock Rating

Sangamo Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (50.00%), 6 Hold (42.86%), 1 Sell (7.14%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 6 7 Strong Sell Sell Hold Buy Strong Buy

SGMO Price Target Upside V Benchmarks

TypeNameUpside
StockSangamo Therapeutics1128.81%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$2.50
Last Closing Price$0.59$0.59$0.59
Upside/Downside--323.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25222--6
Sep, 25222--6
Aug, 25222--6
Jul, 25222--6
Jun, 25232--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 31, 2024Maury RaycroftJefferies$3.00$1.02194.12%408.47%
Dec 31, 2024Yanan ZhuWells Fargo$2.00$1.0296.08%238.98%
Jun 13, 2022Andreas ArgyridesWedbush$5.00$3.7632.98%747.46%
Apr 05, 2022Nicole GerminoTruist Financial$19.00$6.15208.94%3120.34%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 31, 2024H.C. WainwrightBuyBuyhold
Dec 31, 2024JefferiesBuyBuyhold
Dec 31, 2024Cowen & Co.BuyBuyhold
Dec 31, 2024BarclaysOverweightOverweighthold
Oct 23, 2024Cowen & Co.BuyBuyhold
May 15, 2024H.C. WainwrightUnderperformUnderperformhold
Mar 13, 2024H.C. WainwrightBuyBuyhold
Jan 19, 2024Wells FargoSector PerformSector Performhold
Nov 03, 2023RBC CapitalSector Performdowngrade
Feb 27, 2023WedbushOutperformupgrade

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.90$-1.23$-1.25$-1.48$-0.49----
Avg Forecast$-0.82$-1.32$-1.30$-1.38$-0.47$-0.27$-0.26$-0.11$0.19
High Forecast$-0.02$-0.04$-0.49$-1.31$-0.41$-0.08$-0.15$0.20$0.53
Low Forecast$-2.08$-3.34$-2.72$-1.47$-0.55$-0.43$-0.49$-0.35$0.03
Surprise %9.76%-6.82%-3.85%7.25%4.26%----

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$118.19M$110.70M$111.30M$176.23M$57.80M----
Avg Forecast$123.76M$109.54M$110.73M$182.25M$61.99M$73.53M$62.17M$141.08M$246.74M
High Forecast$268.57M$237.71M$204.23M$189.74M$66.32M$136.33M$62.83M$330.61M$578.22M
Low Forecast$31.24M$27.65M$57.63M$176.77M$56.23M$32.46M$61.50M$49.69M$86.90M
Surprise %-4.50%1.06%0.52%-3.30%-6.76%----

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-121.12M$-178.30M$-192.28M$-257.83M$-97.94M----
Avg Forecast$-243.72M$-179.04M$-196.95M$-257.83M$-83.34M$-61.71M$-83.13M$-48.47M$33.73M
High Forecast$-194.98M$-143.23M$-157.56M$-206.26M$-70.93M$-14.27M$-25.69M$34.45M$92.63M
Low Forecast$-292.46M$-214.85M$-236.34M$-309.40M$-95.75M$-74.91M$-86.12M$-61.52M$5.32M
Surprise %-50.30%-0.42%-2.37%-17.52%----

SGMO Forecast FAQ

Is Sangamo Therapeutics stock a buy?

Sangamo Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 6 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Sangamo Therapeutics is a favorable investment for most analysts.

What is Sangamo Therapeutics's price target?

Sangamo Therapeutics's price target, set by 14 Wall Street analysts, averages $7.25 over the next 12 months. The price target range spans from $2 at the low end to $19 at the high end, suggesting a potential 1128.81% change from the previous closing price of $0.59.

How does Sangamo Therapeutics stock forecast compare to its benchmarks?

Sangamo Therapeutics's stock forecast shows a 1128.81% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Sangamo Therapeutics over the past three months?

  • October 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Sangamo Therapeutics’s EPS forecast?

Sangamo Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.27, marking a -44.90% decrease from the reported $-0.49 in 2024. Estimates for the following years are $-0.26 in 2026, $-0.11 in 2027, and $0.19 in 2028.

What is Sangamo Therapeutics’s revenue forecast?

Sangamo Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $73.53M, reflecting a 27.21% increase from the reported $57.8M in 2024. The forecast for 2026 is $62.17M, followed by $141.08M for 2027, and $246.74M for 2028.

What is Sangamo Therapeutics’s net income forecast?

Sangamo Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-61.715M, representing a -36.99% decrease from the reported $-97.941M in 2024. Projections indicate $-83.133M in 2026, $-48.471M in 2027, and $33.73M in 2028.